Skip to content
Screener

Exelixis EXEL Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Pfizer logo
PfizerPFE
-$2.86B+45.4%
Kura Oncology logo
Kura OncologyKURA
$69K-51.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$79.85M+3,992,200%
Immunome logo
ImmunomeIMNM
-$135K-100%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$16M-69.2%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$12.93B+27.4%
Enterprise value$12.82B+26.1%
P/E15×-1.8×
P/S5.3×+0.8×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash flows from financing activities:
Payments for repurchases of common stock(753,326)(585,858)
Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan22,91237,710
Taxes paid related to net share settlement of equity awards(70,572)(63,018)
Net cash used in financing activities(800,986)(611,166)
Net decrease in cash and cash equivalents(201,040)(52,941)
Cash and cash equivalents at beginning of period482,488217,374
Cash and cash equivalents at end of period$281,448$164,433

Item 1. Financial Statements.

FAQ

What is Exelixis's financing cash flow?
Exelixis (EXEL) reported financing cash flow of -$343.88M in Q2 2026.
How has Exelixis's financing cash flow changed year-over-year?
Exelixis's financing cash flow decreased by 8.7% year-over-year, from -$316.34M to -$343.88M.
What is the long-term trend for Exelixis's financing cash flow?
Over 3 years (2021 to 2025), Exelixis's financing cash flow has grown at a 303.1% compound annual growth rate (CAGR), from -$14.8M to -$969.59M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Exelixis's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude